Figure 1. The flowchart for complete screening process.

Warfarin and DOACs show similar safety and efficacy in left ventricular thrombus

By Ahmed El-Medany

A meta-analysis by Xuan et al, evaluated the safety and efficacy of direct oral anticoagulants (DOACs) versus warfarin in patients with left ventricular thrombus (LVT).

A total of 6 studies (837 patients; mean age 60.2 ± 1.6 years; 77.2% male) were included. There was no significant difference found with regards to thromboembolic events (relative risk [RR] 1.69, 95% confidence interval [CI] 0.94–3.06, P 0.08, heterogeneity (I2) 12.7%), rate of resolution of thrombus (RR 1.08, 95% CI 0.96–1.21, P 0.21, I2 4.8%), and clinically significant bleeding (RR 0.70, 95% CI 0.37–1.32, P 0.27, I2 0%) between the warfarin and DOAC group.

Furthermore, no significant difference in all-cause mortality was found between the two groups (RR 1.24, 95% CI 0.79–1.96, P 0.35, I2 0.0%).

Read more on this on the Frontiers In Cardiovascular Medicine Website

Zhou K, Zhang X, Xiao Y, Li D, Song G. Effectiveness and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in patients with left ventricular thrombus: A meta-analysis. Thrombosis Research. 2021 Jan 1;197:185-91.